|1.||Colli, Enrico: 8 articles (07/2012 - 02/2005)|
|2.||Adorini, Luciano: 7 articles (04/2009 - 02/2005)|
|3.||Maggi, Mario: 7 articles (04/2009 - 02/2005)|
|4.||Andersson, Karl-Erik: 4 articles (07/2012 - 02/2005)|
|5.||Adorini, L: 4 articles (06/2010 - 04/2004)|
|6.||Amuchastegui, Susana: 4 articles (04/2009 - 07/2005)|
|7.||Morelli, Annamaria: 4 articles (04/2009 - 02/2005)|
|8.||Fibbi, Benedetta: 4 articles (04/2009 - 02/2005)|
|9.||Maggi, M: 3 articles (06/2010 - 04/2004)|
|10.||Vannelli, Gabriella Barbara: 3 articles (04/2009 - 02/2005)|
03/01/2007 - "We have documented the anti-inflammatory effects of BXL-628 also in animal models of autoimmune prostatitis, observing a significant reduction of intra-prostatic cell infiltrate following administration of this VDR agonist, at normocalcemic doses, in mice with already established disease. "
06/01/2009 - "In a phase IIa trial in patients with prostatitis, elocalcitol significantly reduced levels of IL-8 in semen, suggesting improved quality and forward motility of sperm. "
12/15/2006 - "Finally, CD4(+) splenic T cells from Elocalcitol-treated NOD mice show decreased ability, upon adoptive transfer into NOD.SCID recipients, to induce autoimmune prostatitis, paralleled by a reduced capacity to produce IFN-gamma in response to prostate steroid-binding protein. "
12/15/2006 - "On the basis of on the marked inhibitory activity of the vitamin D receptor agonist Elocalcitol on basal and growth factor-induced proliferation of human prostate cells and on its potent anti-inflammatory properties, we have tested its capacity to treat experimental autoimmune prostatitis (EAP) induced by injection of prostate homogenate-CFA in nonobese diabetic (NOD) mice. "
12/15/2006 - "Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol."
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
05/01/2008 - "Elocalcitol (BXL-628): a novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia."
06/01/2009 - "In preclinical studies, elocalcitol inhibited the androgen-dependent and androgen-independent proliferation of benign prostatic hyperplasia (BPH) cells more potently than finasteride, a 5alpha-reductase inhibitor. "
01/01/2006 - "To evaluate the effect of BXL628, a vitamin D3 analog, on prostate volume in patients with benign prostatic hyperplasia (BPH). "
01/01/2006 - "BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial."
06/01/2006 - "Our results demonstrate that the vitamin D analogue BXL-628 is able to suppress KGF-induced proliferation and invasion of AI-PC cells in vitro, prospecting a possible use of the drug, which is currently in phase II clinical studies for benign prostatic hyperplasia, in the treatment of advanced prostate cancer."
|3.||Overactive Urinary Bladder (Overactive Bladder)
07/01/2012 - "Although the primary endpoint was not achieved, elocalcitol appears to be an effective and well-tolerated drug for the treatment of women with overactive bladder and idiopathic detrusor overactivity. "
07/01/2012 - "Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity."
06/01/2009 - "However, phase IIb trial data from patients with overactive bladder (OAB) were less promising: elocalcitol failed to meet the primary endpoint despite demonstrating good efficacy in a phase IIa trial. "
07/01/2012 - "In humans, elocalcitol was demonstrated with a very good safety profile but only exhibited limited efficacy on LUTS in patients with BPH and overactive bladder (OAB). "
07/01/2012 - "To evaluate the efficacy and safety of elocalcitol in the treatment of women with overactive bladder and idiopathic detrusor overactivity. "
|4.||Male Infertility (Male Sterility)
06/01/2009 - "Given the novel mechanism of action, efficacy profile and improved tolerability of elocalcitol over existing classes of drugs, the compound could have potentially added to the armamentarium in the expanding therapeutic markets of BPH, OAB and male infertility. "
06/01/2009 - "Based largely on these disappointing data, BioXell decided to terminate all further clinical development of elocalcitol, including an uncompleted phase IIa trial in patients with male infertility. "
06/01/2009 - "Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility."
02/01/2005 - "Because BXL-628 inhibited prostate growth without interfering with androgen signaling, it represents a new option for benign prostate hyperplasia (BPH) therapy. "
07/15/2005 - "BXL-628 was also more effective in inhibiting intimal hyperplasia, leading to approximately 80% reduction compared with vehicle-treated controls, an effect significantly superior to dexamethasone administration. "
04/01/2004 - "Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia."
|1.||Interleukin-8 (Interleukin 8)
|2.||Calcitriol Receptors (Calcitriol Receptor)
|8.||Cholecalciferol (Vitamin D3)
|1.||Investigational Therapies (Experimental Therapy)